JP Morgan Reiterates Overweight on Mead Johnson

JP Morgan maintains its Overweight rating on Mead Johnson

in light of confusing reports of a second baby linked with Enfamil. JP Morgan says, "In our view, this news unfortunately may add some uncertainty to the situation, as many investors we spoke with yesterday were under the impression that all Enfamil products were cleared from discussion regarding the second baby's illness. In fact, only Enfamil Newborn seems to be presumed innocent. We still are curious why no other babies have become sick from Enfamil Newborn – a point of fact that suggests Enfamil may not be the source of the bacterium – but today's information does add some extra confusion to an already-muddled story." MJN closed at $68.76 per share on Thursday.